The reiteration of a Buy rating and maintenance of a $166 price target by a reputable analyst like Gil Blum from Needham is likely to instill confidence among investors and could positively influence Sarepta Therapeutics' stock price in the short term. Analyst ratings, especially with a high price target, often lead to increased investor interest and can drive up the stock price.